Supplementary Table 3 from Modulation of T-Cell Activation by Malignant Melanoma Initiating Cells

Tobias Schatton,Ute Schütte,Natasha Y. Frank,Qian Zhan,André Hoerning,Susanne C. Robles,Jun Zhou,F. Stephen Hodi,Giulio C. Spagnoli,George F. Murphy,Markus H. Frank

DOI: https://doi.org/10.1158/0008-5472.22384281.v1

2023-01-01

Abstract:Supplementary Table 3 from Modulation of T-Cell Activation by Malignant Melanoma Initiating Cells

What problem does this paper attempt to address?

Supplementary Table 2 from Modulation of T-Cell Activation by Malignant Melanoma Initiating Cells

Tobias Schatton,Ute Schütte,Natasha Y. Frank,Qian Zhan,André Hoerning,Susanne C. Robles,Jun Zhou,F. Stephen Hodi,Giulio C. Spagnoli,George F. Murphy,Markus H. Frank

DOI: https://doi.org/10.1158/0008-5472.22384284.v1

2023-01-01

Abstract:Supplementary Table 2 from Modulation of T-Cell Activation by Malignant Melanoma Initiating Cells
Supplementary Table 1 from Modulation of T-Cell Activation by Malignant Melanoma Initiating Cells

Tobias Schatton,Ute Schütte,Natasha Y. Frank,Qian Zhan,André Hoerning,Susanne C. Robles,Jun Zhou,F. Stephen Hodi,Giulio C. Spagnoli,George F. Murphy,Markus H. Frank

DOI: https://doi.org/10.1158/0008-5472.22384287.v1

2023-01-01

Abstract:Supplementary Table 1 from Modulation of T-Cell Activation by Malignant Melanoma Initiating Cells
Supplementary Methods and Materials from Modulation of T-Cell Activation by Malignant Melanoma Initiating Cells

Tobias Schatton,Ute Schütte,Natasha Y. Frank,Qian Zhan,André Hoerning,Susanne C. Robles,Jun Zhou,F. Stephen Hodi,Giulio C. Spagnoli,George F. Murphy,Markus H. Frank

DOI: https://doi.org/10.1158/0008-5472.22384290

2023-01-01

Abstract:Supplementary Methods and Materials from Modulation of T-Cell Activation by Malignant Melanoma Initiating Cells
Supplementary Table 3 from Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases

Inna Smalley,Zhihua Chen,Manali S. Phadke,Jiannong Li,Xiaoqing Yu,Clayton Wyatt,Brittany Evernden,Jane L. Messina,Amod A. Sarnaik,Vernon K. Sondak,Chaomei Zhang,Vincent Law,Nam Tran,Arnold Etame,Robert J.B. Macaulay,Zeynep Eroglu,Peter Forsyth,Paulo C. Rodríguez,Y. Ann Chen,Keiran S.M. Smalley

DOI: https://doi.org/10.1158/1078-0432.22481001

2023-01-01

Abstract:Supplemental Table 3: top genes that differentiate each cluster of T/NK cells
Supplementary Table 1 from Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases

Inna Smalley,Zhihua Chen,Manali S. Phadke,Jiannong Li,Xiaoqing Yu,Clayton Wyatt,Brittany Evernden,Jane L. Messina,Amod A. Sarnaik,Vernon K. Sondak,Chaomei Zhang,Vincent Law,Nam Tran,Arnold Etame,Robert J.B. Macaulay,Zeynep Eroglu,Peter Forsyth,Paulo C. Rodríguez,Yigiang Chen,Keiran S.M. Smalley

DOI: https://doi.org/10.1158/1078-0432.22481007.v1

2023-01-01

Abstract:Supplemental Table 1: Flow Cytometry Antibodies
Supplementary Figure from Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy

Jiannong Li,Inna Smalley,Zhihua Chen,Jheng-Yu Wu,Manali S. Phadke,Jamie K. Teer,Thanh Nguyen,Florian A. Karreth,John M. Koomen,Amod A. Sarnaik,Jonathan S. Zager,Nikhil I. Khushalani,Ahmad A. Tarhini,Vernon K. Sondak,Paulo C. Rodriguez,Jane L. Messina,Y. Ann Chen,Keiran S.M. Smalley

DOI: https://doi.org/10.1158/1078-0432.22486712

2023-01-01

Abstract:Supplementary Figure from Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy
Modulation Of T-Cell Activation By Malignant Melanoma Initiating Cells

Tobias Schatton,Ute Schütte,Natasha Y Frank,Qian Zhan,André Hoerning,Susanne C Robles,Jun Zhou,F Stephen Hodi,Giulio C Spagnoli,George F Murphy,Markus H Frank

DOI: https://doi.org/10.1158/0008-5472.CAN-09-1592

IF: 11.2

2010-01-01

Cancer Research

Abstract:Highly immunogenic cancers such as malignant melanoma are capable of inexorable tumor growth despite the presence of antitumor immunity. Thus, only a restricted minority of tumorigenic malignant cells may possess the phenotypic and functional characteristics needed to modulate tumor-directed immune activation. Here we provide evidence supporting this hypothesis. Tumorigenic ABCB5(+) malignant melanoma initiating cells (MMICs) possessed the capacity to preferentially inhibit IL-2-dependent T-cell activation and to support, in a B7.2-dependent manner, induction of CD4(+)CD25(+)FoxP3(+) regulatory T cells (Tregs). Compared with melanoma bulk cell populations, ABCB5(+) MMICs displayed lower levels of MHC class I, aberrant positivity for MHC class II, and lower expression levels of the melanoma-associated antigens MART-1, ML-IAP, NY-ESO-1, and MAGE-A. Additionally, these tumorigenic ABCB5(+) subpopulations preferentially expressed the costimulatory molecules B7.2 and PD-1, both in established melanoma xenografts and in clinical tumor specimens. In immune activation assays, MMICs inhibited mitogen-dependent human peripheral blood mononuclear cell (PBMC) proliferation and IL-2 production more efficiently than ABCB5(-)melanoma cell populations. Moreover, coculture with ABCB5(+) MMICs increased the abundance of Tregs, in a B7.2 signaling-dependent manner, along with IL-10 production by mitogen-activated PBMCs. Consistent with these findings, MMICs also preferentially inhibited IL-2 production and induced IL-10 secretion by cocultured patient-derived, syngeneic PBMCs. Our findings identify novel T-cell modulatory functions of ABCB5(+) melanoma subpopulations and suggest specific roles for these MMICs in the evasion of antitumor immunity and in cancer immunotherapeutic resistance. Cancer Res; 70(2); 697-708. (C)2010 AACR.
Data from Modulation of T-Cell Activation by Malignant Melanoma Initiating Cells

Tobias Schatton,Ute Schütte,Natasha Y. Frank,Qian Zhan,André Hoerning,Susanne C. Robles,Jun Zhou,F. Stephen Hodi,Giulio C. Spagnoli,George F. Murphy,Markus H. Frank

DOI: https://doi.org/10.1158/0008-5472.c.6500829

2023-01-01

Abstract:AbstractHighly immunogenic cancers such as malignant melanoma are capable of inexorable tumor growth despite the presence of antitumor immunity. Thus, only a restricted minority of tumorigenic malignant cells may possess the phenotypic and functional characteristics needed to modulate tumor-directed immune activation. Here we provide evidence supporting this hypothesis. Tumorigenic ABCB5+ malignant melanoma initiating cells (MMICs) possessed the capacity to preferentially inhibit IL-2–dependent T-cell activation and to support, in a B7.2-dependent manner, induction of CD4+CD25+FoxP3+ regulatory T cells (Tregs). Compared with melanoma bulk cell populations, ABCB5+ MMICs displayed lower levels of MHC class I, aberrant positivity for MHC class II, and lower expression levels of the melanoma-associated antigens MART-1, ML-IAP, NY-ESO-1, and MAGE-A. Additionally, these tumorigenic ABCB5+ subpopulations preferentially expressed the costimulatory molecules B7.2 and PD-1, both in established melanoma xenografts and in clinical tumor specimens. In immune activation assays, MMICs inhibited mitogen-dependent human peripheral blood mononuclear cell (PBMC) proliferation and IL-2 production more efficiently than ABCB5− melanoma cell populations. Moreover, coculture with ABCB5+ MMICs increased the abundance of Tregs, in a B7.2 signaling-dependent manner, along with IL-10 production by mitogen-activated PBMCs. Consistent with these findings, MMICs also preferentially inhibited IL-2 production and induced IL-10 secretion by cocultured patient-derived, syngeneic PBMCs. Our findings identify novel T-cell modulatory functions of ABCB5+ melanoma subpopulations and suggest specific roles for these MMICs in the evasion of antitumor immunity and in cancer immunotherapeutic resistance. Cancer Res; 70(2); 697–708
Supplementary Table 2 from MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer

Mengyu Xie,Hong Zheng,Ranjna Madan-Lala,Wenjie Dai,Nicholas T. Gimbrone,Zhihua Chen,Fumi Kinose,Sarah A. Blackstone,Keiran S.M. Smalley,W. Douglas Cress,Eric B. Haura,Uwe Rix,Amer A. Beg

DOI: https://doi.org/10.1158/0008-5472.22422747

2023-01-01

Abstract:Drug screening data used in Figure 2 are shown, including drug names, cell viability and expression levels of chemokines.
Supplementary Figure S2 from Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non–Small Cell Lung Cancer

Jhanelle E. Gray,Andreas Saltos,Tawee Tanvetyanon,Eric B. Haura,Ben Creelan,Scott J. Antonia,Michael Shafique,Hong Zheng,Wenjie Dai,James J. Saller,Zhihua Chen,Nishan Tchekmedyian,Kristen Goas,Ram Thapa,Theresa A. Boyle,Dung-Tsa Chen,Amer A. Beg

DOI: https://doi.org/10.1158/1078-0432.22471758.v1

2023-01-01

Abstract:Approach to assess levels of monocytic and PMN MDSC in patient PBMCs.
Modulation of Cell Signaling Networks after CTLA4 Blockade in Patients with Metastatic Melanoma

Begoña Comin-Anduix,Hooman Sazegar,Thinle Chodon,Douglas Matsunaga,Jason Jalil,Erika von Euw,Helena Escuin-Ordinas,Robert Balderas,Bartosz Chmielowski,Jesus Gomez-Navarro,Richard C. Koya,Antoni Ribas

DOI: https://doi.org/10.1371/journal.pone.0012711

IF: 3.7

2010-09-15

PLoS ONE

Abstract:BACKGROUND: The effects on cell signalling networks upon blockade of cytotoxic T lymphocyte-associated antigen-4 (CTLA4) using the monoclonal antibody tremelimumab were studied in peripheral blood mononuclear cell (PBMC) samples from patients with metastatic melanoma.METHODOLOGY/PRINCIPAL: Findings Intracellular flow cytometry was used to detect phosphorylated (p) signaling molecules downstream of the T cell receptor (TCR) and cytokine receptors. PBMC from tremelimumab-treated patients were characterized by increase in pp38, pSTAT1 and pSTAT3, and decrease in pLck, pERK1/2 and pSTAT5 levels. These changes were noted in CD4 and CD8 T lymphocytes but also in CD14 monocytes. A divergent pattern of phosphorylation of Zap70, LAT, Akt and STAT6 was noted in patients with or without an objective tumor response.CONCLUSIONS/SIGNIFICANCE: The administration of the CTLA4-blocking antibody tremelimumab to patients with metastatic melanoma influences signaling networks downstream of the TCR and cytokine receptors both in T cells and monocytes. The strong modulation of signaling networks in monocytes suggests that this cell subset may be involved in clinical responses to CTLA4 blockade.CLINICAL TRIAL REGISTRATION: clinicaltrials.gov; Registration numbers NCT00090896 and NCT00471887.

multidisciplinary sciences
Supplementary Table S3 from Two Types of Human Malignant Melanoma Cell Lines Revealed by Expression Patterns of Mitochondrial and Survival-Apoptosis Genes: Implications for Malignant Melanoma Therapy

David M. Su,Qiuyang Zhang,Xuexi Wang,Ping He,Yuelin Jack Zhu,Jianxiong Zhao,Owen M. Rennert,Yan A. Su

DOI: https://doi.org/10.1158/1535-7163.22485233

2023-01-01

Abstract:Supplementary Table S3 from Two types of human malignant melanoma cell lines revealed by expression patterns of mitochondrial and survival-apoptosis genes: implications for malignant melanoma therapy
T Cell Chemotactic Response in Patients with Primary and Metastatic Malignant Melanoma

Min Zheng,Guojun Sun,Suiqing Cai,UllerR M

1998-01-01

Chinese Journal of Dermatology

Abstract:Objective \r\nTo address the question whether circulating T-cells from the patients with primary and metastatic malignant melanoma show altered chemotaxis to monocyte chemotactic protein 1 (MCP-1) and its relation to tumor infiltrating lymphocyte (TIL) and metastasis.\r\n\r\n\r\nMethods \r\nChemotactic responsiveness of T-cells towards MCP-1 and immuno-histochemistry study were investigated in patients with primary and metastatic melanoma compared to patients with basal cell carcinoma and healthy persons.\r\n\r\n\r\nResults \r\nT-cells from primary and metastatic melanoma patients showed a significantly decreased chemotactic migration towards MCP-1 and that T-cells from patients with basal cell carcinoma showed normal chemotactic response. Immuno-histochemistry study showed that there was no correlation between the density of TIL and the decreased chemotaxis of circulating T-cells to MCP-1 in patients with primary melanoma.\r\n\r\n\r\nConclusion \r\nCirculating T-cells from patients with primary and metastatic malignant melanoma show a MCP-1-specific decrease in chemotactic migration, this may be due to abnormal expression or modulation of MCP-1-receptor on these cells.\r\n\r\n\r\nKey words: \r\nMelanoma; T-Lymphocytes; Chemotaxis
Supplementary Tables from Targeting Autocrine CCL5–CCR5 Axis Reprograms Immunosuppressive Myeloid Cells and Reinvigorates Antitumor Immunity

Yi Ban,Junhua Mai,Xin Li,Marisa Mitchell-Flack,Tuo Zhang,Lixing Zhang,Lotfi Chouchane,Mauro Ferrari,Haifa Shen,Xiaojing Ma

DOI: https://doi.org/10.1158/0008-5472.22412618.v1

2023-01-01

Abstract:This table contains patient clinical data and auto rejection rates of 4T1 tumors.
Interaction of Molecular Alterations with Immune Response in Melanoma

Robert A. Szczepaniak Sloane,Vancheswaran Gopalakrishnan,Sangeetha M. Reddy,Xue Zhang,Alexandre Reuben,Jennifer A. Wargo

DOI: https://doi.org/10.1002/cncr.30681

IF: 6.9209

2017-01-01

Cancer

Abstract:Major advances have been made in melanoma treatment with the use of molecularly targeted therapies and immunotherapies, and numerous regimens are now approved by the US Food and Drug Administration for patients with stage IV disease. However, therapeutic resistance remains an issue to both classes of agents, and reliable biomarkers of therapeutic response and resistance are lacking. Mechanistic insights are being gained through preclinical studies and translational research, offering potential strategies to enhance responses and survival in treated patients. A comprehensive understanding of the immune effects of common mutations at play in melanoma is critical, as is an appreciation of the molecular mechanisms contributing to therapeutic resistance to immunotherapy. These mechanisms and the interplay between them are discussed herein. (c) 2017 American Cancer Society.
Supplementary Table S5 from Two Types of Human Malignant Melanoma Cell Lines Revealed by Expression Patterns of Mitochondrial and Survival-Apoptosis Genes: Implications for Malignant Melanoma Therapy

David M. Su,Qiuyang Zhang,Xuexi Wang,Ping He,Yuelin Jack Zhu,Jianxiong Zhao,Owen M. Rennert,Yan A. Su

DOI: https://doi.org/10.1158/1535-7163.22485227

2023-01-01

Abstract:Supplementary Table S5 from Two types of human malignant melanoma cell lines revealed by expression patterns of mitochondrial and survival-apoptosis genes: implications for malignant melanoma therapy
Supplementary Tables 1 - 4 from LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses

Feng Xu,Jing Liu,Di Liu,Biao Liu,Min Wang,Zhiyuan Hu,Xuemei Du,Li Tang,Fuchu He

DOI: https://doi.org/10.1158/0008-5472.22399923.v1

2023-01-01

Abstract:<p>PDF file - 71KB, Supplementary Table 1 Characteristics of 7 types of cancer patient in cancer survey array. Supplementary Table 2 Characteristics of patient in melanoma RNA chip. Supplementary Table 3 Characteristics of patient in melanoma IHC chip. Supplementary Table 4. Characteristics of patient in flow cytometry analysis.</p>
Supplementary Table 1 from Mavorixafor, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with Melanoma

Robert H.I. Andtbacka,Yan Wang,Robert H. Pierce,Jean S. Campbell,Melinda Yushak,Mohammed Milhem,Merrick I. Ross,Katie Niland,Robert D. Arbeit,Sudha Parasuraman,Kris Bickley,Cecilia C.S. Yeung,Lauri Aicher,Kimberly S. Smythe,Lu Gan

DOI: https://doi.org/10.1158/2767-9764.22545773.v1

2023-01-01

Abstract:Antibody panels used for mIF analyses.
Supplementary Figure 2 from LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses

Feng Xu,Jing Liu,Di Liu,Biao Liu,Min Wang,Zhiyuan Hu,Xuemei Du,Li Tang,Fuchu He

DOI: https://doi.org/10.1158/0008-5472.22399947.v1

2023-01-01

Abstract:PDF file - 31KB, Supplementary Figure 2 Determination of concentration of IL-6 and IL-10 within tumor.
Modulation of innate immunity in the tumor microenvironment

Elena Gonzalez-Gugel,Mansi Saxena,Nina Bhardwaj

DOI: https://doi.org/10.1007/s00262-016-1859-9

2016-06-25

Abstract:A recent report from the Center for Disease Control identified melanoma as being among the highest causes of cancer-related mortalities in the USA. While interventions such as checkpoint blockade have made substantial impact in terms of improving response rates and overall survival, a significant number of patients fail to respond to treatment or become resistant to therapy. A better understanding of the tumor microenvironment in these patients becomes imperative for identifying immune suppressive mechanisms that impact the development of effective anti-tumor immune responses. We have investigated innate immune cells (dendritic cells, NK cells) in the tumor microenvironment (TME) in order to devise effective targeted anticancer immune therapies. We find that matrix metalloproteinase-2 (MMP-2), secreted from melanoma cells and stromal cells, cleaves IFNAR1 and stimulates TLR-2 on dendritic cells (DC) within the TME. Both these events independently culminate in programing the DCs to promote pro-tumorigenic TH2 T cell differentiation. In addition, we have shown that NK cells become functionally exhausted in melanoma patients. We identified the expression of Tim-3 as one of the factors responsible for NK cell exhaustion and showed that anti-Tim3 antibodies partially reversed this exhaustion. We have initiated local intervention strategies such as intra-tumoral administration of DC activating Poly-ICLC and compared the efficacy of different TLR agonists and melanoma antigens for use as combination tumor vaccine in clinical trials. Such approaches will provide a unique insight into tumor biology and will facilitate in development of highly effective and cell type-specific immune therapies.

Supplementary Table 3 from Modulation of T-Cell Activation by Malignant Melanoma Initiating Cells

Supplementary Table 2 from Modulation of T-Cell Activation by Malignant Melanoma Initiating Cells

Supplementary Table 1 from Modulation of T-Cell Activation by Malignant Melanoma Initiating Cells

Supplementary Methods and Materials from Modulation of T-Cell Activation by Malignant Melanoma Initiating Cells

Supplementary Table 3 from Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases

Supplementary Table 1 from Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases

Supplementary Figure from Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy

Modulation Of T-Cell Activation By Malignant Melanoma Initiating Cells

Data from Modulation of T-Cell Activation by Malignant Melanoma Initiating Cells

Supplementary Table 2 from MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer

Supplementary Figure S2 from Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non–Small Cell Lung Cancer

Modulation of Cell Signaling Networks after CTLA4 Blockade in Patients with Metastatic Melanoma

Supplementary Table S3 from Two Types of Human Malignant Melanoma Cell Lines Revealed by Expression Patterns of Mitochondrial and Survival-Apoptosis Genes: Implications for Malignant Melanoma Therapy

T Cell Chemotactic Response in Patients with Primary and Metastatic Malignant Melanoma

Supplementary Tables from Targeting Autocrine CCL5–CCR5 Axis Reprograms Immunosuppressive Myeloid Cells and Reinvigorates Antitumor Immunity

Interaction of Molecular Alterations with Immune Response in Melanoma

Supplementary Table S5 from Two Types of Human Malignant Melanoma Cell Lines Revealed by Expression Patterns of Mitochondrial and Survival-Apoptosis Genes: Implications for Malignant Melanoma Therapy

Supplementary Tables 1 - 4 from LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses

Supplementary Table 1 from Mavorixafor, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with Melanoma

Supplementary Figure 2 from LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses

Modulation of innate immunity in the tumor microenvironment